PR

LLUX.PK Negotiating to Acquire Weedmaps.com

COSTA MESA, CALIFORNIA--(Marketwire - Sept. 3, 2010) - LC LUXURIES LIMITED (PINK SHEETS:LLUX) (the "Company") announces that its newly established subsidiary, US Cannabis, Inc., a Nevada corporation, has entered into formal negotiations with Weedmaps, LLC, to acquire the domain name "weedmaps.com" and the current operating website. Weedmaps.com has specialized in search engine optimization since 2009 and has a significant presence as it relates to the cannabis industry. At this time, the terms and conditions of the acquisition are still being negotiated and no terms or conditions of the acquisition have been agreed upon between the parties.

Douglas Francis, the CEO of both the Company and US Cannabis, Inc., stated that, "Weedmaps.com is a perfect fit for our growth model. They have structured an exciting template which. we believe, will expand our internet presence in the cannabis industry."

James Pakulis, President of both the Company and US Cannabis, Inc., agrees that, "Having an equity interest in Weedmaps.com is only natural. We are truly looking forward to consummating a transaction."

Cannabis Science Reports on Multi-Billion Dollar Chronic Pain Market as Canadian Medical Journal Publishes Study That "Smoked Marijuana" is Effective Against Neuropathic Pain That Does Not Respond to Conventional Treatment

COLORADO SPRINGS, Colo., Sept. 1, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, has issued a statement regarding a Canadian study on marijuana and intractable post-traumatic or post-surgery neuropathic pain that did not respond to conventional treatment. In this multi-billion dollar market, this is very encouraging news for Cannabis Science shareholders as even small doses of cannabis provided relief from chronic, neuropathic pain, which may be caused by physical injuries or by anti-viral drugs used to treat HIV/AIDS. Neuropathic pain is also common in cancer patients as a direct result of the cancer, or as a side effect of chemotherapy, radiation or surgery.

Cannabis Science President and CEO Dr. Robert Melamede, PhD., commented, "Obviously, this study gives further support to our plans to work within the multi-billion dollar market of chronic neuropathic pain. As Dr. Ware said at the beginning of the CMAJ article, cannabis sativa has been used to treat pain since the third millennium BC, so it is all the more outrageous that it has taken so long for such a study to be done, and it could only be used by patients who did not respond to anything else. Why do they have to suffer so much to prove what almost all medical marijuana users already know?"

Cannabis Science Raising Working Capital and Entering European Medical Cannabis Market With Expanded Opportunity Among Europe's 500 Million Citizens Following German Approval

COLORADO SPRINGS, Colo., Aug. 30, 2010 (GLOBE NEWSWIRE) -- Cannabis Science Inc. (OTCBB:CBIS) ("Cannabis Science, CBIS, or Company"), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce that the Company is currently raising working capital in the European market and pursuing listings on the Frankfurt and other major European exchanges.

Cannabis Science is vigorously seeking entry into the European medical cannabis market on the footsteps of GW Pharmaceuticals plc (GWPharm.com), a UK based commercial cannabinoid pharmaceutical company, which paved the way with the introduction and approval of its product, Sativex® in the UK and now Spain, which gave its regulatory approval on July 28, 2010. Currently Sativex® is approved in the UK and Spain as a prescription medicine for treatment of MS spasticity and in Canada for relief of neuropathic pain and advanced cancer pain.

Medical Marijuana Inc Launches the Next Phase of The Hemp Network With Over 1,750 Agents

FOOTHILL RANCH, CA--(Marketwire - August 30, 2010) - Medical Marijuana Inc (PINKSHEETS: MJNA) through their division The Hemp Network® (www.thehempnetwork.com), has successfully launched the next phase of their soft launch.

"Now we can test the systems, introduce the lead off product line, Nature's Ancient Wisdom™, and move toward final integration in 20 days," said President Don Steinberg. "For the past months, we have been consulting with respected immunologists, doctors and formulators in the development of what we believe are some of the finest whole foods available, all of which contain the 'super food' hemp. Our focus is on pure and natural ingredients, bringing the highest quality at the best prices."

Director of Product Development Dianna Kaplan stated, "We are now offering natural products that contain plant materials that have been brought to light after decades of obscurity and now warmly accepted in this age of nutritional awareness and environmental stewardship. These products have the potential for huge market share as did the 'Fish Oils' of the 1980s, or the 'Omegas' of the 1990s."

LLUX.PK Commences Operations in New Subsidiary U.S. Cannabis, Inc.

COSTA MESA, CALIFORNIA--(Marketwire - Aug. 27, 2010) - LC LUXURIES LIMITED (PINK SHEETS:LLUX) (the "Company") announces that its newly established subsidiary, U.S. Cannabis, Inc., a Nevada corporation, will begin supporting the U.S. medical marijuana market through the management of medical clinics in California. The clinics will be staffed by California Licensed, board-certified physicians and will meet or exceed all regulatory standards. The Company's intention is to set a standard by which the management of medical marijuana clinics will be measured. The Company intends to be managing 10 clinics before the calendar year end, 2010.

The Company's CEO, Douglas Francis, stated, "The Company is extremely excited with the expansion of our health and beauty model to now include the medical marijuana segment of health care. This sector may be the fastest growing sector of health care with some estimates exceeding $45 billion in annual revenues and, we are very serious about playing a significant role in that growth and beyond." President James Pakulis stated, "We believe this is an extraordinary opportunity for us to showcase our abilities as well as exhibit the advanced range of services we will be offering in a very young business sector. Our hope is that those service strengths will create a level of care, specialized to the client, unlike any other customer health service experience."

Cannabis Science Plans European Expansion As German News Service Reports Health Ministry to Approve Medical Marijuana; No Change in Law Required Opening the Door to Europe; "It's Time to Bring Cannabis Out From the Shadows"

COLORADO SPRINGS, Colo., Aug. 24, 2010 (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS), a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to report that Germany is becoming the latest country to approve medical cannabis.

Deutsche Welle, Germany's international broadcaster, which provides media services throughout the world, has reported that "the German health ministry has announced plans to legalize medical use of marijuana, prompting praise from advocates for patients with chronic pain and terminal illnesses."

http://www.dw-world.de/dw/article/0,,5921523,00.html

According to Deutsche Welle, Health Minister Philipp Roesler said, "The plan could be carried out by a simple change in the ministry's policy, and that no change in German law was necessary." He added that "because many other European countries already allow medical cannabis, the process in Germany could go 'quickly in comparison.'"

Amergence Strategic Partner, Altitude OrganicTM, Licenses Five Retail Locations

PHOENIX, AZ and DENVER, CO--(Marketwire - August 24, 2010) - The Amergence Group (PINKSHEETS: AMNG), a company that focuses on developing, nurturing, and rapidly expanding selected emerging or disruptive companies across a wide range of industries and disciplines, announced today that its strategic partner, Altitude Organic Licensing Corp., has licensed its proprietary AO brand to five retail locations. They are:

Denver South -- Located at 2250 South Oneida Street Denver, CO 80224, 303-756-8888. The dispensary website address is http://aomsouth.qwestoffice.net.

Colorado Springs -- Located at 409 S. Nevada Ave., Colorado Springs, CO 80903, 719-434-7918.

Colorado Springs -- Located at 822 W Colorado Ave, Colorado Springs, CO 80903, 719-313-9841.

Colorado Springs -- Located at 204 Mt.View Lane, Unit #10, Colorado Springs, CO 80907, and

San Diego -- Located at 2110 Hancock Street, #201, San Diego, CA 92110, 619-220-7100 with their dispensary web address at http://altitudeorganic.com/.

Cannabis Medical Solutions Announces Multiple Orders for New "MediPayment(TM)" Cards for Medical Marijuana Dispensaries

LOS ANGELES, Aug. 19, 2010 (GLOBE NEWSWIRE) -- Cannabis Medical Solutions Inc. (http://www.cannabismedsolutions.com/) (OTCBB:CMSI), a leading company specializing in both brick-and-mortar and online merchant payment solutions and financial security products for medical marijuana dispensaries and high-risk merchant accounts, today announced that the Company has received multiple orders from medical marijuana dispensaries for the CMSI proprietary "MediPayment" closed loop payment system.

"The CMSI MediPayments™ system will soon prove itself to be the ultimate payment solution for medical marijuana dispensaries operating in licensed jurisdictions throughout the U.S. and abroad. The proprietary payment solution has been under development over the last six months, and is designed to become the "PayPal" payment solution for this industry. Unfortunately, the banking community has not caught up with recent state legislation, thereby creating several hurdles for these businesses to take alternative forms of payment from patients other than cash. MediPayment™ is a closed loop debit system allowing for a card to card transaction between patient and dispensary, virtually eliminating the need for credit card transactions, and is less expensive than ATM, credit cards and other loyalty card programs while providing complete reporting, administrative functions, marketing tracking and bonus rewards. The system which can be installed in minutes will also eliminate fraud and theft associated with cash only operations," stated B. Michael Friedman, CEO for Cannabis Medical Solutions.

Smokefree Innotec Confirms Joint Venture with Cannabis Science, Examines Potential of Medical Cannabis Market

IRVINE, Calif.--(BUSINESS WIRE)--Smokefree Innotec, Inc. (Pink Sheets:SFIO) Thomas Schroepfer, CEO, (http://www.sfio.us or http://www.realsmokefree.com) confirmed today the announcement by the Biotech company Cannabis Science (OTCBB:CBIS) regarding entering into a joint venture agreement to develop and market several high-tech smoke-free vaporized medical cannabis pharmaceutical products, as released by CBIS on August 13. He stated, “Pursuant to the joint venture, Smokefree Innotec Inc will supply its high-tech smoke-free vapor technology devices and Cannabis Science will provide all the medical cannabis extract formulations.”

George Roth, CFO stated, “Our business of designing, developing, manufacturing and marketing hi-tech, nicotine and non-nicotine cigarette-like delivery devices which are completely smoke and vapor-free and tobacco-free, represents an excellent partnering with Cannabis Science to fill their needs for production and distribution in the fourteen US States that currently approve the medical use of cannabis. This partnering further represents our commitment to continue to expand our network of cutting edge technology partners to create ever expanding product lines, for devices delivering both nicotine and herbal therapeutic extracts, as seen on our web site http://www.sfio.us.”

Cannabis Science Signs First Licensing Agreement With RockBrook for Manufacturing, Development, and Distribution of the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado as State Legislation Forces Cancellation of Acquisition

Cannabis Science Signs First Licensing Agreement With RockBrook for Manufacturing, Development, and Distribution of the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado as State Legislation Forces Cancellation of RockBrook Acquisition

COLORADO SPRINGS, Colo., Aug. 18, 2010 (GLOBE NEWSWIRE) -- Cannabis Science Inc. (OTCBB:CBIS) a pioneering US biotech company developing pharmaceutical cannabis products, announces that on August 18, 2010, Cannabis Science signed with RockBrook Inc., its first manufacturing and development license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado. The licensing agreement grants RockBrook the full latitude and rights to manufacture, develop, produce, distribute, and sell products developed from, or based on Cannabis Science formulations, and delivery systems for the Cannabis Science Brand of Pharmaceutical Products and Cannabis Science Ailment Formulations within the State of Colorado.

Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President & CEO said, "Importantly, unlike big pharma, Cannabis Science will be able to immediately begin using data acquired from RockBrook patients using Cannabis Science Brands to evaluate our medical marijuana prior to FDA clinical trials. We are enthusiastic that our relationship with Mr. Pasquale and RockBrook has been established under a licensing and manufacturing agreement that is compliant with the current Colorado regulatory environment. RockBrook will immediately begin marketing and developing new Cannabis Science Brand of Pharmaceutical Products."

Syndicate content